

## Press Release

### CCC Diagnostics, Inc to Present Breast Cancer Study Results at Paris Conference

June 09, 2010 - CCC Diagnostics, in conjunction with Dr. Katherine Tkaczuk of the University of Maryland Greenebaum Cancer Center, will present data describing expanded clinical studies of the DirectHit<sup>®</sup> Panel for Breast Cancer at the 2nd Worldwide Innovative Networking (WIN) in personalized cancer medicine conference on July 7, 2010 in Paris, France. The data being presented at WIN will show that DirectHit can predict the responsiveness of late stage breast cancer patients to two additional classes of chemotherapy drugs, taxanes and 5-FU, with a high degree of accuracy

“The data presented at WIN supports our position that The DirectHit<sup>®</sup> Test Panel for Breast Cancer allows a new approach to drug selection” said John Hughes, President and CEO of CCC Diagnostics. “The information provided by this test supplies crucial information to aid the physician in selecting an effective drug regimen for the individual breast cancer patient.”

About CCC Diagnostics, Inc.

CCC Diagnostics, Inc. was formed in 2004 by a group of scientists from the Johns Hopkins University School of Public Health, and led by the late Dr. Paul O. P. Ts'o, the former Director of the school's Biophysics Division.

CCC Diagnostics, Inc. actively integrates discoveries in diagnostic, therapeutic and information technologies to create innovative approaches to cancer disease management and to enhance the quality of life for cancer patients. Our strategy is to provide effective, personalized chemotherapy treatment recommendations, increasing life quality and decreasing cost through appropriate drug choice.

CCC Diagnostics is located in the Caton Research Park in Baltimore, MD